Could a Higher Willingness-to-Pay for 'Innovative' Therapies in Cost Effectiveness HTAs Help Enable Europe to Retain R&D and Manufacturing?

Name: Could a Higher Willingness-to-Pay for 'Innovative' Therapies in Cost Effectiveness HTAs Help Enable Europe to Retain R&D and Manufacturing?
Start: 2026-11-10T16:45
End: 2026-11-10T17:45
Location: Austria Center Vienna

ISPOR Europe 2026 · 10 November 2026 · 16:45–17:45

Could a Higher Willingness-to-Pay for 'Innovative' Therapies in Cost Effectiveness HTAs Help Enable Europe to Retain R&D and Manufacturing? was a session at ISPOR Europe 2026 on 10 November 2026 in Vienna, with 4 speakers on record.

Speakers

Lieven Annemans — Moderator Ghent University
Natalie Bennett — Speaker Novartis Pharmaceuticals UK Limited
Mark Sculpher — Speaker University of York
Lotte Steuten — Speaker Office of Health Economics